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Summary
Objective: Using human cartilage samples and cultured chondrocytes, to assess the possible involvement of oxidized low-density lipoprotein
(ox-LDL) and lectin-like ox-LDL receptor-1 (LOX-1) in pathogenesis and progression of osteoarthritis (OA).
Methods: Thirty-two cartilage samples were obtained from 16 patients with knee OA, and 12 Control samples from six with femoral neck frac-
ture. LOX-1 mRNA expressions in 12 OA and six Control samples were analyzed by reverse transcription-polymerase chain reaction (RT-
PCR). Immunohistochemistry for ox-LDL and LOX-1 was performed in all samples. The histological OA grade was assessed with the modiﬁed
Mankin score. The relative percentage of the ox-LDL and LOX-1 immunopositive chondrocytes was calculated in all samples. The effects of
ox-LDL on cell viability in cultured human chondrocytes were investigated by the 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide
(MTT) assay and on proteoglycan synthesis by monitoring [35S] sulfate incorporation.
Results: There was a statistically signiﬁcant difference between mean LOX-1/GAPDH (LOX-1/human glyceraldehyde-3-phosphate dehydro-
genase) ratio of OA samples and that of Control samples (40.6% 10.3 and 11.9% 2.8, respectively, P< 0.0001). The mean percentage of
ox-LDL-positive cells was 23.0 15.7% in OA and 4.3 3.7% in Control cells (P¼ 0.0002). The mean percentage of LOX-1-positive cells was
51.7 29.5% in OA and 10.0 8.1% in Control cells (P< 0.0001). Both the ox-LDL immunoreactivity and the LOX-1 immunoreactivity were
signiﬁcantly correlated with the modiﬁed Mankin scores (R2¼ 0.67 and 0.48, respectively; P< 0.0001 for each). ox-LDL signiﬁcantly reduced
the human chondrocyte viability and proteoglycan synthesis, and pretreatment with anti-human LOX-1 monoclonal antibody reversed these
effects.
Conclusion: The ox-LDL/LOX-1 system may be involved in human OA.
ª 2006 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.





Osteoarthritis (OA) represents the most common type of
joint disease. About 900,000 patients are diagnosed with
OA each year in Japan1. The condition is characterized
by loss of cartilage, narrowing of the joint space, subchon-
dral bone sclerosis, and osteophyte growth. Although it is
generally agreed that the OA has a multifactorial patho-
genesis, epidemiological and experimental studies have
suggested the involvement of lipid peroxidation in the
pathogenesis of articular cartilage degeneration. Both
hypercholesterolemia and hypertension are associated with
the risk of knee OA, independent of obesity2. Articular
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Received 19 April 2006; revision accepted 23 July 2006.2manifestations are frequent in familial hypercholesterol-
emia, which is characterized by a decreased removal of
low-density lipoprotein (LDL) from serum, and treatment
with a lipid-lowering diet decreases the incidence of joint
involvement3. The Framingham Knee Osteoarthritis
Cohort Study has demonstrated that a medium- to high-
intake of antioxidants, such as ascorbic acid, b-carotene,
and vitamin E, also reduces the risk of progressive knee
OA4. The content of neutral lipids, including cholesterol
and triglycerides, in the superﬁcial layer of articular carti-
lage increases with aging5,6. An in vitro study showed
that treatment of primary rabbit chondrocytes with a cal-
cium ionophore signiﬁcantly enhances lipid peroxidation
activity and the release of labeled matrix in dose-depen-
dent manner, and that this effect is blocked by vitamin
E, suggesting that lipid peroxidation is related to the
mechanism of matrix degradation and release7. Degrada-
tion of the extracellular matrix is inhibited by the lipid per-
oxidation inhibitors vitamins C and E7,8, and n-3 fatty81
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factors involved in articular cartilage degradation9.
Collectively, these evidences support the hypothesis that
lipid peroxides play a role in the degradation of cartilage
in OA.
Recently, a novel receptor for ox-LDL, designated lectin-
like ox-LDL receptor-1 (LOX-1), was cloned from cultured
bovine aortic endothelial cells10. It has been shown that
ox-LDL binding to this receptor expressed on the surface
of vascular endothelium is involved in endothelial activation
and dysfunction in atherogenesis10,11. Interestingly, Naka-
gawa et al. reported that LOX-1 was expressed and
ox-LDL was noted on chondrocytes in rat zymosan-induced
arthritis (ZIA)12. Treatment with anti-LOX-1 monoclonal an-
tibody suppresses articular cartilage degeneration in ZIA,
suggesting that ox-LDL binding to LOX-1 is involved in
the cartilage degeneration. An in vitro functional study of
ox-LDL and LOX-1 in cultured rat chondrocytes showed
that LOX-1 expression is detectable in basal culture condi-
tions and is enhanced by treatment with ox-LDL and inter-
leukin (IL)-1b13,14. In addition, ox-LDL dose-dependently
reduces rat chondrocyte viability through LOX-1, inducing
nonapoptotic cell death13. Recently, we have demonstrated
that ox-LDL binding to LOX-1 in cultured bovine articular
chondrocytes increases the production of intracellular reac-
tive oxygen species (ROS) resulting in the activation of nu-
clear factor-kB (NF-kB), suggesting that ox-LDL has effects
similar to IL-1b on the degradation of articular cartilage14.
These observations suggest that the ox-LDL/LOX-1 system
may play a signiﬁcant role in both endothelial and chondro-
cyte dysfunction. More recently, Kakinuma et al. reported
that LOX-1 is expressed in rheumatoid arthritis (RA) carti-
lage and ox-LDL can penetrate cartilage matrix and associ-
ate with LOX-115. This study also showed that ox-LDL
enhances matrix metalloprotease (MMP)-3 production
from explant cultures of articular cartilage, and that MMP-
3 production is mediated by LOX-1, suggesting that the as-
sociation of ox-LDL with LOX-1 may modulate cartilage
degradation15.
In the present study, we used immunohistochemistry to
examine localization of chondrocytes associating with ox-
LDL and expressing LOX-1 in articular cartilage from OA
patients and normal humans. We also examined the cor-
relation between the presence of these molecules and
the grade of cartilage degeneration. In addition, we in-
vestigated the effects of ox-LDL on cell viability and pro-
teoglycan synthesis in cultured human chondrocytes. We
found colocalization of chondrocytes associating with ox-
LDL and expressing LOX-1 and signiﬁcant correlations
between the grade of cartilage degradation and the im-
munoreactivity of ox-LDL and LOX-1. Our in vitro studies
showed that ox-LDL reduced cell viability, resulting in
suppression of proteoglycan synthesis in cultured human
chondrocytes, and that this could be reversed by pre-
treatment with anti-human LOX-1 monoclonal antibody.
These results suggest that the ox-LDL/LOX-1 system
may be involved in pathogenesis and progression of
human OA.
Materials and methods
CLINICAL SAMPLES AND HISTOLOGY
Thirty-two cartilage samples were obtained at total
knee arthroplasty from 16 knee joints of patients with
OA, whose mean age was 73.7 5.4 (SD) years and
who had been diagnosed according to the AmericanRheumatism Association criteria16. The OA samples
were obtained from the weight-bearing area of the
medial and lateral condyles of the femur, avoiding ebur-
nated areas of the subchondral bone. Twelve normal
Control cartilage (Control) samples without macroscopic
changes were taken from the weight-bearing area of
six hip joints of patients with femoral neck fracture
(aged 80.3 10.3 years). Information about patients
(gender, age, body mass index and comorbidities inﬂu-
encing to pro/antioxidant status) in the study and Control
groups is shown in Table I. The protocols were approved
by the Kinki University Medical Center Institutional
Review Boards. All samples were cut into 5 mm thick
slices, ﬁxed with 4% paraformaldehyde for 24 h at 4C,
and embedded in parafﬁn wax after decalciﬁcation with
0.5 mol/L of ethylenediaminetetraacetic acid, pH 7.4.
Paraformaldehyde-ﬁxed parafﬁn sections were stained
with hematoxylin/eosin and Safranin O, and subjected
to histological evaluation according to the modiﬁed
Mankin scoring system17.
REVERSE TRANSCRIPTION-POLYMERASE CHAIN REACTION
(RT-PCR) FOR LOX-1 MRNA
Total RNA (1 mg) was directly extracted from articular
cartilage samples (12 OA and six Control samples) by
the acid guanidiumephenolechloroform method using
Isogen (Nippon Gene, Toyama, Japan) according to the
manufacturer’s protocol. The extracted total RNA was re-
verse-transcribed using OneStep RT-PCR kit (Qiagen
Japan, Tokyo, Japan). Reverse-transcribed material (1.5 mL)
was ampliﬁed with Taq DNA polymerase (Bex, Tokyo,
Japan) using a primer pair speciﬁc to human LOX-1 (sense
primer, 50-TTACTCTCCATGGTGGTGCC-30; antisense
primer, 50-AGCTTCTTCTGCTTGTTGCC-30). The PCR
product was 271 bp in length. For PCR, 27 cycles were
used at 94C for 30 s, 55C for 30 s, and 72C for
30 s. In the same experiments, human glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) was ampliﬁed
with equal efﬁciency as internal references of LOX-1
mRNA. A primer pair for human GAPDH was used
(sense primer, 50-CCATCACCATCTTCGGAGC-30; anti-
sense primer, 50-GGAAGGCCATGCCAGTGAGC-30). The
PCR product was 483 bp in length. The RT-PCR-ampli-
ﬁed samples were visualized on 1.5% agarose gels using
ethidium bromide. Each LOX-1 mRNA band was normal-
ized with a band of the relative internal reference GAPDH
mRNA. The relative intensities of bands of interest were
analyzed using Gel Doc 2000 (Bio-Rad Labs, Hercules,
CA) and scan analysis software (Biosoft, Ferguson,
MO), and expressed as a ratio to the GAPDH mRNA
band.
IMMUNOHISTOCHEMISTRY
Sections from the 4% paraformaldehyde-ﬁxed samples
(32 OA and 12 Control cartilage samples) were treated
with 80% methanolþ 0.6% H2O2 for 30 min, followed by
treatment with 3.0% H2O2 for 15 min after washing to
block endogenous peroxidase. The sections were then
treated with goat polyclonal antibodies against human
LOX-1 (1/20 dilution; Santa Cruz Biotechnology, Santa
Cruz, CA) at 4C overnight. The primary antibodies were
diluted with antibody diluents containing protein to block
nonspeciﬁc reactions (S2022, DAKO, Glostrup, Denmark).
After the reactions with biotinylated rabbit antibodies
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Information about patients in the study and Control groups
Group No. Gender Age BMI Comorbidity
Study (OA) 1 F 69 20.9 Type C hepatitis
2 M 72 24.4 HT
3 F 80 25.2 HT, HC
4 F 60 25.7 HT
5 F 76 31.4 HT, DM
6 M 77 25.7 HT, arrhythmia
7 F 68 30.4 HT, hyperthyroidism
8 F 77 26.7 HT
9 F 76 25.2 HT, gastric ulcer
10 F 78 22.8 n.p.
11 F 79 24.6 HT, DM, HC
12 F 72 19.2 HT, AS
13 F 64 33.2 HC
14 M 76 21.8 HT
15 F 77 26.9 HT, HC
16 F 76 25.4 n.p.
Control (FNF) 1 F 92 19.6 HT, AS, HC
2 F 90 17.8 HT, AS
3 F 70 23.5 n.p.
4 F 71 18.6 HT
5 M 72 23.7 DM, HT, RF
6 F 87 19.4 HT
OA: Osteoarthritis, FNF: Femoral neck fracture, HT: Hypertension, HC: Hypercholesterolemia, DM: Diabetes mellitus, AS: Atherosclerosis,
and RF: Renal failure.against goat immunoglobulin G (IgG) (1/500 dilution;
DAKO) at room temperature for 30 min, the sections were
reacted with horseradish peroxidase-labeled streptavidin
(DAKO) at room temperature for 15 min. The color was de-
veloped with 3,3-diaminobenzidine tetrahydrochloride (DAB)
in 50 mmol/L of TriseHCl, pH 7.6, 0.15 mol/L of NaCl, con-
taining 0.05% Tween. Counterstaining was performed with
hematoxylin. As a control, sections were reacted by replac-
ing the ﬁrst antibodies with nonimmune goat IgG (DAKO) at
room temperature for 2 h before the immunostaining. For
immunohistochemistry of ox-LDL, parafﬁn sections of OA
(32 samples) and Control cartilage (12 samples) were re-
acted with mouse immunoglobulin M (IgM)IgM monoclonal
anti-human oxidized-phosphatidylcholine (ox-PC) antibody
(DLH3, 1/150 dilution), and then treated with biotinylated
goat IgG to mouse IgG (1/200 dilution). The methods of
DLH3 antibody production and speciﬁcity testing have
been reported previously18. As a control, primary antibodies
were replaced with nonimmune mouse IgG (Santa Cruz).
After the reactions, the sections were incubated with horse-
radish peroxidase-labeled streptavidin and the color was
developed with DAB as described above. Moreover, to con-
ﬁrm that DLH3 positive cells are identical to ox-LDL positive
cells, double staining of chondrocytes with DLH3 (1/150
dilution) and goat polyclonal antibodies against human
apoB-100 and -48 (1/20 dilution; Santa Cruz) was per-
formed in parafﬁn sections of OA cartilage (ﬁve samples).
The colors of ox-PC and apoB were developed with DAB
and First red, respectively.
PREPARATION OF LDL AND OX-LDL
Human LDL (density 1.019e1.063) was isolated from
fresh plasma by sequential ultracentrifugation as described
previously10. LDL was oxidized at a concentration of 3 mg
protein/mL by exposure to 7.5 mM CuSO4 for 20 h at
37C. Oxidation was monitored by measuring the amountof thiobarbituric acid-reactive substances (10.7 nmol/mg
protein) produced, and their greater mobilities because of
the increased negative charge on agarose gel electrophore-
sis were compared with native LDL (n-LDL); the relative
electrophoretic mobility was 3.25.
HUMAN ARTICULAR CHONDROCYTE CULTURES
Human articular chondrocyte culture was performed
using commercially available cryopreserved human chon-
drocytes according to the manufacturer’s instruction
(NHAC-kn, Cambrex Corp., East Rutherford, NJ). After
thawing of cells in a 37C water bath, resuspended chon-
drocytes were seeded at a density of 1 104/cm2 in the
growth culture media (CGM BulletKit, Cambrex Corp.) and
incubated at 37C in a humidiﬁed 5% CO2 incubator.
3-(4,5-DIMETHYLTHIAZOLYL-2)-2,5-DIPHENYLTETRAZOLIUM
BROMIDE (MTT) ASSAY
The effect of ox-LDL on cell viability of human chondro-
cytes was assessed using an MTT assay kit (MTT viable
cell count kit, Nacalai Tesque Corp., Kyoto, Japan). This
procedure uses the pale yellow tetrazolium salt MTT,
which is cleaved by enzymes present in the endoplasmic
reticulum and mitochondria to form a dark blue formazan
product. Chondrocytes dispensed into a 96-well culture
ﬂask at a density of 1 104/cm2 were incubated at 37C
in a humidiﬁed 5% CO2 incubator. Once cells reached
70% conﬂuence, the culture media were replaced with se-
rum-free Dulbecco’s modiﬁed Eagle’s medium (DMEM).
Cells were stimulated with ox-LDL or n-LDL at various
concentrations (0, 10, 50, or 100 mg/mL) for 24 h at
37C. To elucidate whether the effects are mediated
through LOX-1, cells were preincubated with anti-human
LOX-1 antibody (JTX92, 40 mg/mL) for 2 h, and then stim-
ulated with ox-LDL at various concentrations (0, 10, 50, or
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100 mL DMEM/F-12 supplemented with 10 mg/mL MTT
for another 4 h at 37C. Dark blue formazan products
were dissolved in 100 mL aliquots of 0.04 N HCl/isopropa-
nol and the optical density (OD)570 was measured using
a micro-plate reader (Spectra Classic, Tecan Group Ltd.,
Zurich, Switzerland).
PROTEOGLYCAN SYNTHESIS
Proteoglycan synthesis was measured by monitoring
[35S] sulfate incorporation. Chondrocytes seeded into
12-well culture ﬂasks at a density of 1 104/cm2 were
cultured in the growth media at 37C in a humidiﬁed
5% CO2 incubator to 70% conﬂuence. To evaluate the
effect of n-LDL and ox-LDL on proteoglycan synthesis,
the chondrocytes were simultaneously incubated in the
presence of n-LDL or ox-LDL at various concentrations
(0, 10, 50, or 100 mg/mL) for 24 h; 0.74 kBq/mL [35S] sul-
fate (NEN Life Science Products, Boston, MA) was
added for the ﬁnal 4 h. The media were collected and
cell layers were washed three times with ice-cold phos-
phate buffered saline (PBS). Using a rubber policeman,
the cells were then placed in 1 mL of PBS and sonicated
for 30 s at 0C. After addition of 5 mL emulsifying scintil-
lation cocktail (Ultima Gold, PerkinElmer Japan, Osaka,
Japan), the newly synthesized proteoglycans present
within the cells were measured by assessing the incorpo-
ration of [35S] sulfate into cetylpyridinium chloride (CPC)-
precipitable material with a liquid scintillation counter
(Beckman LS5000, GMI Inc., Ramsey, MN). To elucidate
whether these effects are mediated through LOX-1, cells
were preincubated with anti-human LOX-1 antibody
(JTX92, 40 mg/mL) for 2 h, and then stimulated with ox-
LDL at various concentrations (0, 10, 50, or 100 mg/mL)
for 24 h.STATISTICAL ANALYSIS
Comparisons of mean percentages of immunostained
chondrocytes, mean cell viability and mean proteoglycan
synthesis were analyzed using Student’s t tests with a statis-
tic analyzing software (Statview ver. 4.02, SAS Institute,
Cary, NC). Correlation between immunoreactivity of ox-
LDL and OA grades and correlation between immunoreac-
tivity of LOX-1 and OA grade were analyzed with the same
software. Data are expressed as the mean SD.
Results
EXPRESSION OF LOX-1 mRNA in OA and Control
cartilage samples
The expression of LOX-1 mRNA was examined by RT-
PCR using total RNA extracted directly from OA (n¼ 12)
and Control (n¼ 6) cartilage samples. LOX-1 mRNA was
expressed in all samples from both OA patients and Con-
trols [Fig. 1(A)]. The speciﬁc ampliﬁcation from the LOX-1
mRNA was conﬁrmed by sequencing the ampliﬁed DNA
products (data not shown). For quantiﬁcation of LOX-1
mRNA expression, the relative intensities of LOX-1 mRNA
bands were analyzed with scan analysis software and ex-
pressed as a ratio to the GAPDH mRNA band. There was
a statistically signiﬁcant difference between mean LOX-1/
GAPDH ratio of OA samples and that of Control cartilage
samples [40.6% 10.3, n¼ 12 and 11.9% 2.8, n¼ 6, re-
spectively, Student’s unpaired t test, P< 0.0001, Fig. 1(B)].
EVALUATION OF OA AND CONTROL CARTILAGE USING
THE MODIFIED MANKIN SCORING SYSTEM
The 32 cartilage specimens from nonosteophytic areas of
OA cartilage (16 patients) had the typical OA changes such
as surface irregularities, ﬁbrillation, ﬁssuring, and reductionFig. 1. LOX-1 mRNA expression in OA and Control cartilage samples. (A) RT-PCR for the expression of LOX-1 mRNA in OA and Control
samples. Total RNA was extracted from OA and Control cartilage and reverse-transcribed into cDNA followed by a PCR reaction using a spe-
ciﬁc primer for LOX-1. LOX-1 mRNA expression was detected in all OA and Control samples. (B) For quantiﬁcation, the relative intensities of
LOX-1 mRNA bands were analyzed with scan analysis software and expressed as a ratio to the GAPDH mRNA band. Error bars indicate
standard deviations. *: P< 0.0001 by Student’s unpaired t test.
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samples ranged from 2 to 19 (9.2 5.3, n¼ 32). The 12
samples from the six Control cartilage samples showed
few or no microscopic changes and the Mankin scores
were 0e2 (0.8 0.9, n¼ 12).
DOUBLE IMMUNOSTAINING OF ox-PC and apoB
in OA cartilage
To conﬁrm that ox-PC-immunopositive chondrocytes are
identical to ox-LDL-positive chondrocytes, we performed
double staining of ox-PC and apoB in ﬁve OA samples us-
ing the DLH3 and anti-human apoB antibody. The localiza-
tion of ox-PC positive cells and apoB positive cells
coincided [Fig. 2(A) and (B)], and immunopositive cells re-
acted simultaneously with the DLH3 and anti-apoB antibody
[Fig. 2(C)]. No staining was observed with nonimmune goat
IgG, conﬁrming the speciﬁcity of the ox-PC and the apoB
immunostaining [Fig. 2(D)].
IMMUNOLOCALIZATION OF ox-LDL positive cells in
OA and Control cartilage
Immunostaining of ox-LDL using DLH3 antibody was
positive in 10 of 12 (83%) of the Control samples. How-
ever, the percentage of the immunostained chondrocytes
relative to all the cells showed that only a few chondro-
cytes in the superﬁcial zone (4.3 3.7%, n¼ 12) wereimmunostained [Fig. 3(A)]. In OA samples, all samples dis-
played ox-LDL immunostaining. Immunohistochemistry
demonstrated that OA chondrocytes associated with
ox-LDL localized mainly in the superﬁcial and transitional
zones in all samples [Fig. 3(B)]. Some chondrocytes local-
ized to the radial zone were stained when the cartilage
had deep ﬁssures reaching this zone. Clustered chondro-
cytes close to the ﬁssures stained frequently with DLH3
[Fig. 3(C)]. No staining was observed with nonimmune
goat IgG, conﬁrming the speciﬁcity of the DLH3 antibody
[Fig. 3(D)]. The mean percentage of positive-immuno-
stained chondrocytes was 23% of the total chondrocytes
(23.0 15.7%, n¼ 32). The percentage of ox-LDL positive
chondrocytes was signiﬁcantly higher in the OA than in the
Control cartilage samples (Student’s unpaired t test,
P¼ 0.0002).
The percentage of ox-PC immunopositive chondrocytes
was signiﬁcantly correlated with the modiﬁed Mankin score
[R2¼ 0.67, n¼ 44, P< 0.0001; Fig. 4(A)].
IMMUNOLOCALIZATION OF LOX-1 POSITIVE CELLS
IN OA AND CONTROL CARTILAGE
All Control samples stained positively for LOX-1. How-
ever, the percentage of immunostained chondrocytes rela-
tive to all chondrocytes was low in the superﬁcial,
transitional, and radial zones (10.0 8.1%, n¼ 12)
[Fig. 5(A)]. Immunohistochemistry demonstrated that LOX-1Double staining x400 x400




Fig. 2. Double immunostaining of ox-PC and apoB in OA cartilage. To conﬁrm that ox-PC-positive chondrocytes are identical to ox-LDL-pos-
itive chondrocytes, double staining of ox-PC and apoB was performed in ﬁve OA samples. (A) Ox-PC single immunostaining colored by DAB.
(B) apoB single immunostaining colored by First red. (C) Double staining for ox-PC and apoB. Immunopositive cells reacted simultaneously
with anti-human ox-PC antibody (DLH3) and anti-human apoB polyclonal antibody. (D) Negative control using the nonimmune goat IgG as the
primary antibody. Magniﬁcation is 400.






Fig. 3. Immunolocalization of ox-LDL in OA and Control cartilage. Immunostaining was performed as described in Materials and methods.
(A) Control cartilage, modiﬁed Mankin score 0. Only a few chondrocytes in the superﬁcial zone (arrowheads) are stained. Magniﬁcation is
40. (B) OA cartilage, modiﬁed Mankin score 14. Chondrocytes from the superﬁcial to upper radial zones are stained (arrowheads). Magni-
ﬁcation is 40. (C) OA cartilage from the same patient as in (B). Clustered chondrocytes in the transitional and radial zones are stained
(arrows). Magniﬁcation is 400. (D) OA cartilage from the same patient as in (B). Negative control using the nonimmune goat IgG as the
primary antibody; no staining is observed. Magniﬁcation is 400.localized to the OA chondrocytes mainly in the superﬁcial
and transitional zones in all samples. LOX-1-positive chon-
drocytes were sometimes observed in the radial zone,
which appeared to be histologically normal [Fig. 5(B)].
Many clustered chondrocytes close to the ﬁssures were la-
beled with anti-LOX-1 polyclonal antibody [Fig. 5(C)]. No
staining was observed with nonimmune goat IgG, conﬁrm-
ing the speciﬁcity of the LOX-1 immunostaining
[Fig. 5(D)]. The percentage of positive-immunostained
chondrocytes relative to all cells was about 50%
(51.7 29.5%, n¼ 32) in the OA samples. The percentage
of the LOX-1 positive chondrocytes was signiﬁcantly higher
in the OA than in the Control cartilage (Student’s unpaired
t test, P< 0.0001).
The percentage of ox-PC immunostained chondrocytes
was signiﬁcantly correlated with the modiﬁed Mankin score
[R2¼ 0.48, n¼ 44, P< 0.0001; Fig. 4(B)].
EFFECTS OFOX-LDL ONCELL VIABILITY AND PROTEOGLYCAN
SYNTHESIS OF CULTURED HUMAN CHONDROCYTES
Various concentrations (0, 10, 50, or 100 mg/mL) of either
ox-LDL or n-LDL were added to human primary cultured
chondrocytes and the changes in cell viability were as-
sessed by the MTT assay. ox-LDL signiﬁcantly reduced
chondrocyte viability at 50 and 100 mg/mL [n¼ 3,
P¼ 0.002 and 0.004, respectively; Fig. 6(A)]; n-LDL did
not alter chondrocyte viability. Pretreatment with anti-human LOX-1 monoclonal antibody (JTX92) signiﬁcantly re-
versed the effects of ox-LDL at both concentrations [n¼ 3,
P¼ 0.003 and 0.014, respectively; Fig. 6(A)], suggesting
that LOX-1 mediates the reduction of cell viability induced
by ox-LDL.
In addition, we investigated the effect of various concen-
trations of ox-LDL (0, 10, 50, or 100 mg/mL) on proteogly-
can synthesis in cultured human chondrocytes 24 h after
the addition of ox-LDL. Proteoglycan synthesis was as-
sayed by monitoring [35S] sulfate incorporation. ox-LDL
at 50 and 100 mg/mL signiﬁcantly suppressed proteoglycan
synthesis [n¼ 3, P¼ 0.002 and 0.002, respectively;
Fig. 6(B)], whereas n-LDL did not. Anti-human LOX-1
monoclonal antibody (JTX92) signiﬁcantly reversed this
suppression of proteoglycan synthesis by 50 and 100 mg/
mL ox-LDL [n¼ 3, P¼ 0.006 and 0.010, respectively;
Fig. 6(B)].
Discussion
In the present study, the anti-human ox-PC mouse
monoclonal antibody (DLH3) was used as the primary an-
tibody for ox-LDL immunostaining, which has been used
as an antibody for ox-LDL staining in atherosclerotic le-
sions18e21. Speciﬁcity testing of DLH3 for ox-LDL has
been reported previously18. Moreover, to conﬁrm that
ox-PC immunopositive chondrocytes are identical to
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ing of ox-PC and ApoB-100 protein. The immunoreactivity
of ox-PC in chondrocytes coincided completely with that
of apoB and immunopositive cells reacted simultaneously
with the DLH3 and anti-human apoB antibody, indicating
that ox-PC-positive chondrocytes can be regarded as
ox-LDL-positive cells in OA cartilage; this is similar to
data showing that ox-PC-positive macrophages and
foam cells are ox-LDL-positive in atherosclerotic
lesions18e21.
The RT-PCR analysis demonstrated that LOX-1 mRNA
was expressed in all OA and Control samples. While, after
normalization to GAPDH mRNA, the mean LOX-1 mRNA
expression was estimated to be 3.4-fold in OA samples
vs Control samples, suggesting that some normal human
chondrocytes, at least in elderly persons, express LOX-1
mRNA in a basal level and the expression increases in
OA chondrocytes. In immunohistochemical studies, LOX-
1 staining was found in all OA and Control samples. The
mean percentage of LOX-1-immunopositive cells was sig-
niﬁcantly greater in the OA samples than in the Control
Fig. 4. Correlations between ox-LDL and LOX-1 immunoreactivities
with the modiﬁed Mankin score. (A) Signiﬁcant correlation between
ox-LDL immunoreactivity and the modiﬁed Mankin score by the lin-
ear regression analysis (R2¼ 0.67, n¼ 44, P< 0.0001). Closed cir-
cles indicate OA and open circles indicate Control samples. (B)
Signiﬁcant correlation between LOX-1 immunoreactivity and the
modiﬁed Mankin score by linear regression analysis (R2¼ 0.48,
n¼ 44, P< 0.0001). Closed squares indicate OA and open squares
indicate Control samples.samples. The percentage of LOX-1-positive cells in carti-
lage samples was also signiﬁcantly correlated with the
OA grades measured by the Mankin score. Furthermore,
the mean percentage of ox-LDL-immunopositive cells
was also signiﬁcantly greater in the OA samples than in
the Control samples. The percentage of ox-LDL-immuno-
positive cells in cartilage samples was signiﬁcantly corre-
lated with the OA grades measured by the Mankin
score. These results suggest that the ox-LDL/LOX-1
ligand-receptor system may be involved in the pathogene-
sis and progression of OA because LOX-1 is only one re-
ceptor for ox-LDL known to be expressed in chondrocytes
and previous in vitro studies have demonstrated that the
system could play some roles in the degeneration of
cartilage12e15,23.
Localization of chondrocytes associating with ox-LDL
and expressing LOX-1 generally coincided in OA and Con-
trol cartilage samples, although LOX-1-positive chondro-
cytes were distributed more widely and deeper than
ox-LDL-positive cells in both OA and Control samples
(Figs. 3 and 5). That is, a number of LOX-1-positive but
ox-LDL-negative chondrocytes were observed in cartilage
samples, although few chondrocytes stained negatively
to LOX-1 and positively to ox-LDL. In addition, ox-LDL im-
munoreactivity was more strongly correlated with the OA
grades than was LOX-1 immunoreactivity (R2¼ 0.67 and
0.48, respectively), indicating that ox-LDL binding to
LOX-1 may be involved in cartilage degeneration, but
that expression of LOX-1 itself may not be involved. The
predominantly surface immunolocalization of ox-LDL may
indicate that ox-LDL in synovial ﬂuid penetrates the carti-
lage matrix and associates with LOX-1 expressed in chon-
drocytes. It has been reported that ﬂuorescent dye-labeled
ox-LDL permeates the cartilage matrix and binds to chon-
drocytes in explant cultures15. However, it is still unclear
where ox-LDL originates. There are three possible modes
of association between ox-LDL and articular chondrocytes.
First, it is likely that ox-LDL in the systemic circulating
blood19,21,22 enters the joint ﬂuid through the synovial vas-
culature. Second, LDL in the systemic circulating blood
might enter the joint ﬂuid and be modiﬁed oxidatively in
the inﬂamed joint cavity24; the resultant ox-LDL might
then penetrate the cartilage matrix and associate with
chondrocytes. Third, LDL penetrating the degraded carti-
lage matrix might be oxidatively modiﬁed by ROS pro-
duced by chondrocytes and the resultant ox-LDL could
associate with LOX-1 in chondrocytes. It has been re-
ported that chondrocytes can produce ROS upon stimula-
tion by a variety of factors including proinﬂammatory
cytokines14,25, ox-LDL14, growth factors26, and mechanical
stimuli such as cyclic tensile stress27. The last mechanism
of oxidative modiﬁcation of ox-LDL and association with
chondrocytes via LOX-1 is now under investigation in
our institute.
The expression of LOX-1 in human knee cartilage was
recently demonstrated in RA patients, where ox-LDL asso-
ciates with articular chondrocytes15. In the study, cartilage
samples obtained from non-weight bearing regions of the
distal femur and proximal tibia in patients with RA were
compared with those from non-weight bearing regions in
patients with OA. They mentioned that fewer cells were
stained with both anti-LOX-1 and anti-ox-LDL antibodies
in OA and normal cartilage, but most RA chondrocytes
stained positively with these antibodies. We examined
samples obtained from weight-bearing areas of the distal
femur in OA patients, which showed macroscopic
changes, with Control normal cartilage samples taken






Fig. 5. Immunolocalization of LOX-1 in Control and OA cartilage. Immunostaining was performed as described in Materials and methods. (A)
Control cartilage, modiﬁed Mankin score 0. Only a few chondrocytes in the superﬁcial and transitional zones (arrowheads) are stained. Mag-
niﬁcation is 40. (B) OA cartilage, modiﬁed Mankin score 15. Chondrocytes from the superﬁcial to radial zones are stained (arrowheads).
Magniﬁcation is 40. (C) OA cartilage from the same patient as in (B). Clustered chondrocytes in the transitional and radial zones are stained
(arrows). Magniﬁcation is 400. (D) OA cartilage from the patient as in (B). Negative control using the nonimmune goat IgG as the primary
antibody; no staining is observed. Magniﬁcation is 400.from individuals with no macroscopic changes of the fem-
oral head. The present study demonstrated that ox-LDL
associates with articular chondrocytes in human OA carti-
lage and that the immunoreactivity of ox-LDL is correlated
with the degree of articular degeneration. The difference
between our data and those of the study mentioned
above15 may relate to differences in the cartilage sampling
sites and anti-ox-LDL and LOX-1 antibodies used for
immunohistochemistry.
It has been demonstrated that oxidative modiﬁcation of
LDL increases its atherogenicity28. Ox-LDL exhibits a num-
ber of speciﬁc biological properties for atherogenicity
in vivo and in vitro including the stimulation of monocyte/
macrophage differentiation to foam cells29, overexpression
of adhesion molecules on endothelial cells30,31, production
of chemoattractant agents32, growth factors and cytokines
involved in the inﬂammatory process33,34, cell prolifera-
tion35, and apoptosis36. Increasing evidence indicates that
the ox-LDL/LOX-1 system in endothelial cells plays a key
role in the pathogenesis of atherosclerosis11,37. Meanwhile,
epidemiological and experimental studies have suggested
that lipid peroxides are involved in the pathogenesis and
the progression of OA2,3,5e9,12e15,23,38. Present in vitro
studies using cultured human articular chondrocytes dem-
onstrated that binding of ox-LDL to LOX-1 reduces cell
viability, resulting in the suppression of proteoglycan
synthesis. Reduced number of chondrocytes, exempliﬁedby empty lacunae, is one of the major characteristics of
OA39, and chondrocyte death is of particular interest in
relation to reduced cell numbers40. In addition, reduced
amount of proteoglycan in cartilage matrix, which is also
one of the major characteristics of OA39, affects mechani-
cal properties of articular cartilage41. These suggest
the possible importance of the ox-LDL/LOX-1 system in
the pathogenesis and the progression of OA. However, the
fact that ox-LDL immunopositive chondrocytes were ob-
served in the superﬁcial and transitional zones and in vicinity
of deep ﬁssures in the radial zone may suggest that the
ox-LDL/LOX-1 system does not have the primary role for
pathogenesis of OA, but the secondary one aggravating
and accelerating the degeneration of cartilage. Release of
aggrecan from the cartilage matrix in early phase of OA
is likely to make cartilage tissue penetrable to ox-LDL, re-
sulting in subsequent penetration and biding of ox-LDL to
LOX-1.
This study is the ﬁrst to show colocalization of chondro-
cytes associating with ox-LDL and expressing LOX-1. Fur-
thermore, signiﬁcant correlations between the grade of
cartilage degradation and the immunoreactivity of ox-LDL
and LOX-1 were noted. Together with previous repor-
ts12e15,23, these results of the present in vivo and in vitro
studies indicate that the ox-LDL/LOX-1 system may be in-
volved in the pathogenesis and the progression of cartilage
degeneration in human OA.
289Osteoarthritis and Cartilage Vol. 15, No. 3References
1. Kawamura H, Sugioka Y, Hirota Y. Epidemiological
study for osteoarthritis: estimation of patient number
(In Japanese). Orthop Surg Trauma 1995;44:12e5.
2. Hart DJ, Doyle DV, Spector TD. Association between
metabolic factors and knee osteoarthritis in
women: the Chingford Study. J Rheumatol 1995;
22:1118e23.
3. Carroll GJ, Bayliss CE. Treatment of the arthropathy of
familial hypercholesterolaemia. Ann Rheum Dis 1983;
42:206e9.
4. McAlindon TE, Jacques P, Zhang Y, Hannan MT,
Aliabadi P, Weissman B, et al. Do antioxidant micronu-
trients protect against the development and
Fig. 6. Effects of ox-LDL on cell viability and proteoglycan synthesis
of cultured human chondrocytes. (A) Changes in cell viability were
assessed by the MTT assay after the addition of various concentra-
tions (0, 10, 50, or 100 mg/mL) of either ox-LDL or n-LDL. Cell via-
bility of chondrocytes was reduced signiﬁcantly by the addition of
ox-LDL in a dose-dependent manner and was reversed signiﬁcantly
by pretreatment with anti-human LOX-1 monoclonal antibody
(JTX92). (B) Changes in proteoglycan synthesis were assessed
by monitoring [35S] sulfate incorporation after addition of various
concentrations (0, 10, 50, or 100 mg/mL) of either ox-LDL or
n-LDL. Proteoglycan synthesis was reduced signiﬁcantly by the ad-
dition of ox-LDL in a dose-dependent manner and reversed signif-
icantly by pretreatment with anti-human LOX-1 monoclonal
antibody (JTX92).progression of knee osteoarthritis? Arthritis Rheum
1996;39:648e56.
5. Stockwell RA. Lipid in the matrix of ageing articular car-
tilage. Nature 1965;207:427e8.
6. Lippiello L. The association of lipid abnormalities with
tissue pathology in human osteoarthritic articular carti-
lage. Metabolism 1991;40:571e6.
7. Tiku ML, Shah R, Allison GT. Evidence linking chondro-
cyte lipid peroxidation to cartilage matrix protein
degradation. Possible role in cartilage aging and the
pathogenesis of osteoarthritis. J Biol Chem 2000;
275:20069e76.
8. Tiku ML, Gupta S, Deshmukh DR. Aggrecan degrada-
tion in chondrocytes is mediated by reactive oxygen
species and protected by antioxidants. Free Radic
Res 1999;30:395e405.
9. Curtis CL, Hughes CE, Flannery CR, Little CB,
Harwood JL, Caterson B. n-3 fatty acid speciﬁcally
modulate catabolic factors involved in articular carti-
lage degradation. J Biol Chem 2000;275:721e4.
10. Sawamura T, Kume N, Aoyama T, Moriwaki H,
Hoshikawa H, Aiba Y, et al. An endothelial receptor
for oxidized low-density lipoprotein. Nature 1997;386:
73e7.
11. Chen M, Masaki T, Sawamura T. LOX-1, the receptor
for oxidized low-density lipoprotein identiﬁed from en-
dothelial cells: implications in endothelial dysfunction
and atherosclerosis [Review]. Pharmacol Ther 2002;
95:89e100.
12. NakagawaT,AkagiM,HoshikawaH,ChenM,YasudaT,
Mukai S, et al. Lectin-like oxidized low-density lipopro-
tein receptor 1 mediates leukocyte inﬁltration and artic-
ular cartilage destruction in rat zymosan-induced
arthritis. Arthritis Rheum 2002;46:2486e94.
13. Nakagawa T, Yasuda T, Hoshikawa H, Shimizu M,
Kakinuma T, Chen M, et al. LOX-1 expressed in cul-
tured rat chondrocytes mediates oxidized LDL-in-
duced cell death-possible role of dephosphorylation
of Akt. Biochem Biophys Res Commun 2002;299:
91e7.
14. Nishimura S, Akagi M, Yoshida K, Hayakawa S,
Sawamura T, Munakata H, et al. Oxidized low-den-
sity lipoprotein (ox-LDL) binding to lectin-like ox-
LDL receptor-1 (LOX-1) in cultured bovine articular
chondrocytes increases production of intracellular re-
active oxygen species (ROS) resulting in the activa-
tion of NF-kappaB. Osteoarthritis Cartilage 2004;12:
568e76.
15. Kakinuma T, Yasuda T, Nakagawa T, Hiramitsu T,
Akiyoshi M, Akagi M, et al. Lectin-like oxidized
low-density lipoprotein receptor 1 mediates matrix
metalloproteinase 3 synthesis enhanced by oxidized
low-density lipoprotein in rheumatoid arthritis cartilage.
Arthritis Rheum 2004;50:3495e503.
16. Altman R, Asch E, Bloch D, Bole G, Borenstein D,
Brandt K, et al. Development of criteria for the clas-
siﬁcation and reporting of osteoarthritis. Classiﬁca-
tion of osteoarthritis of the knee. Diagnostic and
Therapeutic Criteria Committee of the American
Rheumatism Association. Arthritis Rheum 1986;29:
1039e49.
17. Yoshimi T, Kikuchi T, Obara T, Yamaguchi T,
Sakakibara Y, Itoh H, et al. Effects of high-molecu-
lar-weight sodium hyaluronate on experimental osteo-
arthrosis induced by the resection of rabbit anterior
cruciate ligament. Clin Orthop Relat Res 1994;298:
296e304.
290 M. Akagi et al.: Involvement of the ox-LDL/LOX-1 system in OA18. Itabe H, Takeshima E, Iwasaki H, Kimura J, Yoshida Y,
Imanaka T, et al. A monoclonal antibody against oxi-
dized lipoprotein recognizes foam cells in atheroscle-
rotic lesions. Complex formation of oxidized
phosphatidylcholines and polypeptides. J Biol Chem
1994;269:15274e9.
19. Ehara S, Ueda M, Naruko T, Haze K, Itoh A, Otsuka M,
et al. Elevated levels of oxidized low density lipoprotein
show a positive relationship with the severity of acute
coronary syndromes. Circulation 2001;103:1955e60.
20. Sakata N, Imanaga Y, Meng J, Tachikawa Y,
Takebayashi S, Nagai R, et al. Immunohistochemical
localization of different epitopes of advanced glycation
end products in human atherosclerotic lesions. Athero-
sclerosis 1998;141:61e75.
21. Nishi K, Itabe H, Uno M, Kitazato KT, Horiguchi H,
Shinno K, et al. Oxidized LDL in carotid plaques and
plasma associates with plaque instability. Arterioscler
Thromb Vasc Biol 2002;22:1649e54.
22. Itabe H, Yamamoto H, Imanaka T, Shimamura K,
Uchiyama H, Kimura J, et al. Sensitive detection of ox-
idatively modiﬁed low density lipoprotein using a mono-
clonal antibody. J Lipid Res 1996 Jan;37(1):45e53.
23. Akagi M, Nishimura S, Yoshida K, Kakinuma T,
Sawamura T, Munakata H, et al. Cyclic tensile stretch
load and oxidized low density lipoprotein synergistically
induce lectin-like oxidized LDL receptor-1 in cultured
bovine chondrocytes, resulting in decreased cell viabil-
ity and glycosaminoglycan synthesis. J Orthop Res
2006;24:1782e90.
24. James MJ, van Reyk D, Rye KA, Dean RT, Cleland LG,
Barter PJ, et al. Low density lipoprotein of synovial
ﬂuid in inﬂammatory joint disease is mildly oxidized.
Lipids 1998;33:1115e21.
25. Tiku ML, Liesch JB, Robertson FM. Production of
hydrogen peroxide by rabbit articular chondrocytes.
Enhancement by cytokines. J Immunol 1990;145:
690e6.
26. Li WQ, Qureshi HY, Liacini A, Dehnade F, Zafarullah M.
Transforming growth factor beta-1 induction of tissue
inhibitor of metalloproteinases 3 in articular chondro-
cytes is mediated by reactive oxygen species. Free
Radic Biol Med 2004;37:196e207.
27. Yamazaki K, Fukuda K, Matsukawa M, Hara F,
Matsushita T, Yamamoto N, et al. Cyclic tensile stretch
loaded on bovine chondrocytes causes depolymeriza-
tion of hyaluronan: involvement of reactive oxygen
species. Arthritis Rheum 2003;48:3151e8.
28. Steinberg D, Parthasarathy S, Carew TE, Khoo JC,
Witztum JL. Beyond cholesterol. Modiﬁcations of
low-density lipoprotein that increase its atherogenicity
[Review]. N Engl J Med 1989;320:915e24.
29. Tontonoz P, Nagy L, Alvarez JG, Thomazy VA,
Evans RM. PPAR gamma promotes monocyte/macro-
phage differentiation and uptake of oxidized LDL. Cell
1998;93:241e52.30. Li D, Chen H, Romeo F, Sawamura T, Saldeen T,
Mehta JL. Statins modulate oxidized low-density lipo-
protein-mediated adhesion molecule expression in hu-
man coronary artery endothelial cells: role of LOX-1.
J Pharmacol Exp Ther 2002;302:601e5.
31. Khan BV, Parthasarathy SS, Alexander RW,
Medford RM. Modiﬁed low density lipoprotein and its
constituents augment cytokine-activated vascular cell
adhesion molecule-1 gene expression in human
vascular endothelial cells. J Clin Invest 1995;95:
1262e70.
32. Li D, Mehta JL. Antisense to LOX-1 inhibits oxidized
LDL-mediated upregulation of monocyte chemoattrac-
tant protein-1 and monocyte adhesion to human coro-
nary artery endothelial cells. Circulation 2000;101:
2889e95.
33. Inoue M, Itoh H, Tanaka T, Chun TH, Doi K,
Fukunaga Y, et al. Oxidized LDL regulates vascular
endothelial growth factor expression in human macro-
phages and endothelial cells through activation of
peroxisome proliferator-activated receptor-gamma.
Arterioscler Thromb Vasc Biol 2001;21:560e6.
34. Hajjar DP, Haberland ME. Lipoprotein trafﬁcking in vas-
cular cells. Molecular Trojan horses and cellular sabo-
teurs [Review]. J Biol Chem 1997;272:22975e8.
35. Auge N, Garcia V, Maupas-Schwalm F, Levade T,
Salvayre R, Negre-Salvayre A. Oxidized LDL-induced
smooth muscle cell proliferation involves the EGF re-
ceptor/PI-3 kinase/Akt and the sphingolipid signaling
pathways. Arterioscler Thromb Vasc Biol 2002;22:
1990e5.
36. Li D, Yang B, Mehta JL. Ox-LDL induces apoptosis in
human coronary artery endothelial cells: role of PKC,
PTK, bcl-2, and Fas. Am J Physiol 1998;275:
H568e76.
37. Mehta JL, Chen J, Hermonat PL, Romeo F, Novelli G.
Lectin-like oxidized low-density lipoprotein receptor-1
(LOX-1): a critical player in the development of athero-
sclerosis and related disorders [Review]. Cardiovasc
Res 2006;69:36e45.
38. Henrotin YE, Bruckner P, Pujol JP. The role of reactive
oxygen species in homeostasis and degradation of
cartilage [Review]. Osteoarthritis Cartilage 2003;11:
747e55.
39. Mankin HJ, Dorfman H, Lippiello L, Zarins A. Biochem-
ical and metabolic abnormalities in articular cartilage
from osteoarthritic human hips. II. Correlation of
morphology with biochemical and metabolic data.
J Bone Joint Surg Am 1971;53:523e37.
40. Blanco FJ, Ochs RL, Schwarz H, Lotz M. Chondrocyte
apoptosis induced by nitric oxide. Am J Pathol 1995;
146:75e85.
41. Armstrong CG, Mow VC. Variations in the intrinsic me-
chanical properties of human articular cartilage with
age, degeneration, and water content. J Bone Joint
Surg Am 1982;64:88e94.
